E25Bio
E25Bio is a Cambridge, MA-based biotechnology company founded in 2018 that develops rapid diagnostic tests for epidemic fever viruses, serving global health, clinical, and pandemic preparedness markets from a small (1-10 employee) R&D operation.
- Company typePrivate
- Founded2026
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What E25Bio does
E25Bio is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that specializes in the development of rapid diagnostic tests for epidemic fever viruses, such as dengue, Zika, and related pathogens. The company operates with a small team (1-10 employees) and is privately held. Its core offering centers on rapid, point-of-care diagnostic assays designed to enable faster detection of epidemic-prone febrile illnesses, addressing an unmet need in outbreak response and clinical triage in both developed and resource-limited settings.
The company has secured approximately $10.1M across three funding rounds between 2019 and 2020. Its seed round in August 2019 was led by The Engine (MIT's tough-tech venture fund), with participation from Alumni Ventures and Castor Ventures, anchoring E25Bio within MIT's diagnostics and bioengineering ecosystem. A March 2020 round of $2M was led by Khosla Ventures with Blue Ivy Ventures, followed by a $5.82M round in August 2020 from the Bill & Melinda Gates Foundation and SBIR, signaling strategic alignment with global health and pandemic preparedness priorities.
The business model is structured around grant-funded and venture-backed R&D, with the long-term monetization pathway implicitly tied to commercialization of diagnostic test products through clinical, government, and global health channels. The company is led by co-founder and CEO Bobby Brooke Herrera alongside co-founder Lee Gehrke, combining operational and scientific leadership. Pricing, customer segments, and go-to-market details are not disclosed in the available data, consistent with a pre-commercial stage diagnostics developer.
E25Bio firmographics
Firmographics- Name
- E25Bio
- Legal name
- SUMO777
- Website
- https://e25bio.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- E25Bio is a Cambridge, MA-based biotechnology company founded in 2018 that develops rapid diagnostic tests for epidemic fever viruses, serving global health, clinical, and pandemic preparedness markets from a small (1-10 employee) R&D operation.
- Ownership category
- akta.pro rank
E25Bio industry classification
Industry- Product category
- Rapid Infectious Disease Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
Keywords
Where E25Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
E25Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
E25Bio product offering
Product offeringCore offering
E25Bio develops rapid diagnostic tests for epidemic fever viruses, focused on point-of-care detection of infectious disease pathogens. The company's core work is in assay and kit development intended for outbreak and frontline clinical use. Diagnostic products are sold to institutional customers such as public health agencies, hospitals, and research organizations.
Differentiator
Problem solved
Functional benefit
Products and services
- Rapid diagnostic tests for epidemic fever viruses
Companies that use E25Bio
Customer profileIdeal customer profiles1 record
E25Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
E25Bio partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
E25Bio competitors and assessment
Company assessmentBroad incumbents
- Cepheid (Danaher): A leading molecular diagnostics company (owned by Danaher) whose GeneXpert system is widely deployed for infectious disease testing including outbreak pathogens — the dominant incumbent in rapid molecular diagnostics that E25Bio competes against.
- BioFire Diagnostics (bioMérieux): bioMérieux subsidiary operating the FilmArray syndromic panel platform for infectious disease diagnostics, including panels covering fever-causing pathogens — directly comparable in target market (rapid syndromic infectious disease testing).
- QIAGEN: Global molecular diagnostics and sample-preparation leader with significant infectious disease test portfolio including outbreak pathogen assays — a broad incumbent competing for the same customer channels as E25Bio.
- Abbott (Diagnostics): Diversified diagnostics giant whose ID NOW platform provides rapid molecular testing for influenza, RSV, and other infectious agents — a broad incumbent shaping rapid-test procurement standards in the same market segment.
Emerging players
- Mammoth Biosciences: CRISPR-based diagnostics company developing rapid molecular tests for infectious diseases, including fever viruses. Comparable as a venture-backed emerging player in decentralized nucleic-acid-based rapid diagnostics.
- Sherlock Biosciences: CRISPR- and synthetic biology-driven diagnostics company building rapid, field-deployable tests for infectious diseases — closely aligned with E25Bio's mission of decentralized rapid testing for outbreak pathogens.
- Akonni Biosystems: Developer of rapid molecular diagnostic systems for infectious diseases including respiratory and fever pathogens, focused on low-cost, portable platforms for global health — comparable in product profile and target LMIC markets.
- Inflammatix: Host-response diagnostics company developing rapid tests to distinguish bacterial vs viral infections — comparable as a venture-backed diagnostics startup targeting rapid infectious disease decision-making.
- Baebies: Diagnostics company developing rapid, near-patient testing platforms for newborn screening and infectious diseases — comparable in focus on rapid, decentralized diagnostic platforms and global health applications.
Regional players
- Corgenix / EKF Diagnostics: EKF Diagnostics' Corgenix unit develops rapid immunodiagnostic tests targeting epidemic and neglected infectious diseases (e.g., Ebola, dengue) — closely comparable in niche focus on outbreak-related rapid diagnostics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
E25Bio social profiles
Digital presenceE25Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
E25Bio leadership team
Management profileNumber of profiles
Profiles2 records
E25Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
E25Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about E25Bio
What does E25Bio do?
E25Bio develops rapid diagnostic tests for epidemic fever viruses, focused on point-of-care detection of infectious disease pathogens. The company's core work is in assay and kit development intended for outbreak and frontline clinical use. Diagnostic products are sold to institutional customers such as public health agencies, hospitals, and research organizations.
Is E25Bio a public or private company?
E25Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was E25Bio founded?
E25Bio was founded in 2026. It employs 1 to 10 people.
Where is E25Bio based?
E25Bio is headquartered in Cambridge, United States, in the North America region.
Who are E25Bio's main competitors?
Broad incumbents on record are Cepheid (Danaher), BioFire Diagnostics (bioMérieux), QIAGEN and Abbott (Diagnostics). Emerging players are Mammoth Biosciences, Sherlock Biosciences, Akonni Biosystems, Inflammatix and Baebies. Corgenix / EKF Diagnostics is listed as a regional player.
Does E25Bio have an API?
No public API is recorded for E25Bio.
What industry is E25Bio in?
E25Bio's product category is Rapid Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.